Purification of cartilage-derived growth factor by heparin affinity chromatography

HOME

HELP

FEEDBACK

SUBSCRIPTIONS

Purification of cartilage-derived growth factor by heparin affinity chromatography

R Sullivan and M Klagsbrun

Cartilage-derived growth factor (CDGF) was found to bind tightly to columns of immobilized heparin and could be eluted with concentrations of salt in the order of 1.6-1.8 M NaCl. The molecular weight of CDGF was estimated to be 18,000-20,000 by high performance liquid-size exclusion chromatography. The affinity of CDGF for heparin greatly facilitated its purification. Highly purified CDGF active at about 1-2 ng/ml was obtained when crude cartilage extract was applied to heparin- Sepharose and the growth factor activity was recycled over heparin- Sepharose two more times. Analysis by sodium dodecyl sulfate- polyacrylamide gel electrophoresis and silver stain visualization of highly purified CDGF showed one major polypeptide band with a molecular weight of about 19,000 containing over 95% of the protein and one minor polypeptide band containing the rest of the protein. Only the Mr 19,000 polypeptide was active after elution from the polyacrylamide gel. Although CDGF bound tightly to immobilized heparin, it did not bind to immobilized chondroitin sulfate or hyaluronic acid. In addition, CDGF bound to heparin much more tightly than did platelet-derived growth factor even though these two growth factors had similar isoelectric points of about 10. These results suggest that the binding of CDGF to heparin was due to a specific affinity of the 2 molecules for each other.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

D. M. Ornitz and P. J. Marie
FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease
Genes & Dev., June 15, 2002; 16(12): 1446 - 1465.
[Full Text] [PDF]

A. M. Ryan, D. B. Eppler, K. E. Hagler, R. H. Bruner, P. J. Thomford, R. L. Hall, G. M. Shopp, and C. A. O'Neill
Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody
Toxicol Pathol, January 1, 1999; 27(1): 78 - 86.
[Abstract] [PDF]

Y. Hiraki, H. Inoue, J. Kondo, A. Kamizono, Y. Yoshitake, C. Shukunami, and F. Suzuki
A Novel Growth-Promoting Factor Derived from Fetal Bovine Cartilage, Chondromodulin II. PURIFICATION AND AMINO ACID SEQUENCE
J. Biol. Chem., September 13, 1996; 271(37): 22657 - 22662.
[Abstract] [Full Text] [PDF]

M. Poulin, K. Patrie, M. Botelho, R. Tassava, and I. Chiu
Heterogeneity in the expression of fibroblast growth factor receptors during limb regeneration in newts (Notophthalmus viridescens)
Development, January 10, 1993; 119(2): 353 - 361.
[Abstract] [PDF]

S Nakamura, S. Salahuddin, P Biberfeld, B Ensoli, P. Markham, F Wong-Staal, and R. Gallo
Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells
Science, October 21, 1988; 242(4877): 426 - 430.
[Abstract] [PDF]

J Folkman and M Klagsbrun
Angiogenic factors
Science, January 23, 1987; 235(4787): 442 - 447.
[Abstract] [PDF]

J. Abraham, A Mergia, J. Whang, A Tumolo, J Friedman, K. Hjerrild, D Gospodarowicz, and J. Fiddes
Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor
Science, August 1, 1986; 233(4763): 545 - 548.
[Abstract] [PDF]

J.A. Abraham, J.L. Whang, A. Tumolo, A. Mergia, and J.C. Fiddes
Human Basic Fibroblast Growth Factor: Nucleotide Sequence, Genomic Organization, and Expression in Mammalian Cells
Cold Spring Harb Symp Quant Biol, January 1, 1986; 51(0): 657 - 668.
[Abstract] [PDF]